吸入一氧化氮治疗新生儿持续肺动脉高压的研究进展  

Progress of inhaled nitric oxide on treatment of persistent pulmonary hypertension of new-born

作　　者：刘畅[1] 张舒晴 岳冬梅[1] Liu Chang;Zhang Shuqing;Yue Dongmei(Neonatal Department,Shengjing Hospital of China Medical University,Shenyang 110004,China;School of Pharmacy,China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院新生儿科,沈阳110004 [2]中国医科大学药学院,沈阳110004

出　　处：《中国小儿急救医学》2019年第11期858-862,共5页Chinese Pediatric Emergency Medicine

基　　金：辽宁省自然科学基金项目(201602873);辽宁省省直医院改革重点临床科室诊疗能力建设项目(LNCCC-D08-2015)。

摘　　要：新生儿持续肺动脉高压是新生儿期的一种严重疾病,尽管原因多种多样,但相似的病理生理改变为新生儿出生后肺血管阻力升高导致严重的低氧血症,治疗以降低肺血管压力,改善血流动力学为根本.现代治疗如吸入型一氧化氮、高频振荡通气、体外膜肺氧合和(或)其他肺血管扩张剂可降低新生儿持续肺动脉高压的病死率.吸入一氧化氮是治疗新生儿持续肺动脉高压的主要方法,可以有效的改善氧合,减少体外膜肺氧合的需要.不同胎龄吸入一氧化氮治疗效果不尽相同,本文结合国内外吸入一氧化氮治疗新生儿持续肺动脉高压的临床研究进展进行综述.Persistent pulmonary hypertension is a serious disease among new-borns.Despite the variety of causes,similar physiopathologic changes characterize this syndrome:a persistently raised pulmonary vascular resistance after birth,which leads to severe hypoxemia due to extrapulmonary shunting.The fundamental treatment is to reduce pulmonary vascular pressure and improve hemodynamics.Modern treatments such as inhaled nitric oxide,high-frequency oscillation ventilation,extracorporeal membrane oxygenation,and/or other pulmonary vasodilators could reduce mortality in neonatal persisitent pulmonary hypertension(PPHN).Inhaled nitric oxide is the main method for the treatment of PPHN,which can effectively improve oxygenation and reduce the need for extracorporeal membrane oxygenation(ECMO).The effect of inhaled nitric oxide is different with the gestational age changed.This article aims to summarize the clinical research progress of inhaled nitric oxide in the treatment of PPHN.

关 键 词：新生儿持续肺动脉高压 吸入型一氧化氮 肺血管扩张药物 

分 类 号：R72[医药卫生—儿科]